SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

SGLT2 inhibitor use may help stabilize eGFR levels for patients with autosomal dominant polycystic kidney disease and type 2 diabetes, according to study data.“Given its unique pathophysiology, ...

Despite incomplete evidence, longevity enthusiasts are experimenting with SGLT2 inhibitors in their quest to live healthier ...

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question ...

Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

In elderly patients 65 years of age or older with heart failure with reduced ejection fraction (HFrEF), regular use of sodium ...

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in ...

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

A drug commonly used to treat type 2 diabetes may reduce excess fluid in the brains of patients with hydrocephalus, which could help treat the disease less invasively than current treatments, ...